- $6.73bn
- $6.28bn
- $22.29m
U.S. RESEARCH ROUNDUP-Globus Medical, Philip Morris, Vail Resorts
Brief: Arcellx Provides Q4 And Year-End 2022 Results
U.S. STOCKS ON THE MOVE-Mirum, AMC Entertainment, crypto stocks
U.S. STOCKS ON THE MOVE-Meta, Univar, Alphabet, Uber
Stifel initiates coverage on Arcellx with 'buy'
U.S. RESEARCH ROUNDUP-Apollo Global Management, First American Financial, Thomson Reuters
Develop Late-Stage Clinical Cart-Ddbcma In Multiple Myeloma
Arcellx surges on cancer treatment deal with Gilead unit
Arcellx logs highest open on cancer treatment deal with Gilead unit
Brief: Arcellx Enters Into A Stock Purchase Agreement With Gilead Sciences
Brief: Arcellx Announces Robust Responses From Cart-ddBCMA Phase 1 Expansion Trial
Develop Late-Stage Clinical Cart-DDBCMA In Multiple Myeloma
Brief: Arcellx Reports Third Quarter 2022 Financial Results, Business Progress
Brief: Arcellx Inc - Identified Errors In The Accounting For Research And Development Expense And Related Accounts, And Other Immaterial Errors
Brief: Arcellx Announces Presentation Of New Clinical Data From Its Cart-Ddbcma Phase 1 Trial In Patients With Relapsed Or Refractory Multiple Myeloma At The 64Th Ash Annual Meeting And Exposition
Brief: Arcellx Announces Closing Of Upsized Public Offering Of Common Stock And Underwriters' Full Exercise Of Option To Purchase Additional Shares
U.S. STOCKS ON THE MOVE-PROG Holdings Inc, Perion Network Ltd, Olaplex Holdings Inc
U.S. STOCKS ON THE MOVE-Ebix Inc, KLA Corp, Snowflake Inc
U.S. STOCKS ON THE MOVE-Commercial Metals Co, Intel Corp, Mastercard Inc